SCD Ventures

SCD Ventures is a specialized life sciences venture firm and biotechnology incubator focused on the development of novel therapeutics for metabolic and hematological disorders. The company primarily leverages its expertise in the Stearoyl-CoA desaturase-1 (SCD-1) pathway to address unmet needs in nonalcoholic steatohepatitis (NASH) and various dermatological indications. Additionally, SCD Ventures actively invests in and supports the development of next-generation treatments for Sickle Cell Disease (SCD), including gene editing and cell therapy approaches. By combining internal research and development with strategic venture investments, the firm aims to accelerate the translation of early-stage scientific discoveries into clinical-stage assets.